![]() | ![]() |
Formats:
|
|||||||||||||||||||||||||||||||||||||||
Copyright : © 2008 Urban and Vogel. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Two Seemingly Homologous Noncoding RNAs Act Hierarchically to Activate glmS mRNA Translation Max Planck Institute for Infection Biology, RNA Biology Group, Berlin, Germany Sean Eddy, Acadeimc Editor Howard Hughes Medical Institute Janelia Farm, United States of America * To whom correspondence should be addressed. E-mail: vogel/at/mpiib-berlin.mpg.de Received November 6, 2007; Accepted January 29, 2008. This article has been cited by other articles in PMC.Abstract Small noncoding RNAs (sRNA) can function as posttranscriptional activators of gene expression to regulate stress responses and metabolism. We here describe the mechanisms by which two sRNAs, GlmY and GlmZ, activate the Escherichia coli glmS mRNA, coding for an essential enzyme in amino-sugar metabolism. The two sRNAs, although being highly similar in sequence and structure, act in a hierarchical manner. GlmZ, together with the RNA chaperone, Hfq, directly activates glmS mRNA translation by an anti-antisense mechanism. In contrast, GlmY acts upstream of GlmZ and positively regulates glmS by antagonizing GlmZ RNA inactivation. We also report the first example, to our knowledge, of mRNA expression being controlled by the poly(A) status of a chromosomally encoded sRNA. We show that in wild-type cells, GlmY RNA is unstable due to 3′ end polyadenylation; whereas in an E. coli pcnB mutant defective in RNA polyadenylation, GlmY is stabilized and accumulates, which in turn stabilizes GlmZ and causes GlmS overproduction. Our study reveals hierarchical action of two well-conserved sRNAs in a complex regulatory cascade that controls the glmS mRNA. Similar cascades of noncoding RNA regulators may operate in other organisms. Author Summary Hierarchical action of regulators is a fundamental principle in gene expression control, and is well understood in protein-based signaling pathways. We have discovered that small noncoding RNAs (sRNAs), a new class of gene expression regulators, can also act hierarchically and form a regulatory cascade. Two highly similar sRNAs function after transcription to activate the Escherichia coli glmS mRNA, which codes for an essential function in amino-sugar metabolism. It is somewhat unusual for two sRNAs to act upon the same target mRNA, and despite their seeming homology, these two sRNAs (GlmY and GlmZ) employ different molecular mechanisms and function hierarchically to activate glmS expression: GlmZ directly activates glmS translation via disruption of an mRNA structure that inhibits translation, whereas GlmY controls the processing of GlmZ to prevent the inactivation of this direct activator. We also found that GlmY is itself controlled by an RNA processing event (3′ end polyadenylation), which typically destabilizes bacterial RNA. Our data unequivocally demonstrate that E. coli glmS is exceptionally dependent on RNA-based mechanisms for its genetic control. Given the large number of noncoding RNAs of unknown function, we believe that similar regulatory RNA cascades may operate in other organisms. Introduction The posttranscriptional regulation of glmS expression, a gene encoding an essential enzyme (glucosamine-6-phosphate [GlcN-6-P] synthase) in amino-sugar metabolism, has recently attracted much attention. In Bacillus subtilis, the 5′ untranslated region (5′ UTR) of glmS mRNA contains a ribozyme that undergoes self-cleavage in the presence of GlcN-6-P, thereby destabilizing the glmS mRNA [1]. This cis-encoded mechanism of glmS mRNA control and metabolite sensing seems to be highly conserved among Gram-positive species [2]. Whereas Gram-negative bacteria such as E. coli lack the glmS ribozyme [2], recent studies have shown that E. coli glmS is posttranscriptionally controlled by multiple trans-encoded factors, including small noncoding RNAs (sRNAs) and several proteins [3–5]. Functional characterization of two E. coli sRNAs, GlmY and GlmZ (a.k.a. SroF/tke1 [6,7] and RyiA/SraJ [8,9], respectively; Figure 1
The PAP I and YhbJ proteins negatively regulate glmS mRNA expression; E. coli strains carrying functional disruptions of the respective genes overproduce glmS mRNA and GlmS protein [4,5]. PAP I (poly(A) polymerase I encoded by pcnB) is the main enzyme responsible for 3′ end RNA polyadenylation [12], which typically destabilizes bacterial transcripts by facilitating the 3′ → 5′ exonucleolytic degradation of RNA with a structured 3′ end [13,14]. Interestingly, glmS mRNA is markedly stabilized in a PAP I–deficient strain, i.e., E. coli pcnBΔ1 [5]. However, it has been unclear whether glmS mRNA is a substrate of PAP I, and whether polyadenylation directly destabilizes this mRNA in wild-type cells. YhbJ is a protein of unknown function, and appears to act upstream of GlmZ to negatively regulate glmS mRNA [4]. That is, the GlmS overproduction observed in an E. coli ΔyhbJ mutant strain is lost upon glmZ deletion [4]. Collectively, these observations suggested that multiple factors encoded by unlinked loci of the E. coli chromosome control glmS epistasis at the posttranscriptional level. However, whether these factors acted in concert or independently, and how GlmS protein synthesis was ultimately activated, remained to be determined. Here, we show that the regulatory GlmY and GlmZ sRNAs display significant homology of sequence and structure. Despite this apparent homology, we have found that the two RNAs act hierarchically such that GlmY acts upstream of GlmZ, and only GlmZ directly activates glmS mRNA translation. We propose that the main role of GlmY in this novel regulatory RNA cascade is to antagonize YhbJ-dependent inactivation of GlmZ RNA, i.e., the bona fide glmS activator. We also show that PAP I controls the levels of GlmY, and that loss of GlmY RNA polyadenylation causes the previously observed GlmS overproduction in PAP I–deficient E. coli. The hierarchical action of noncoding RNAs described here reveals a novel principle in RNA-based regulatory circuits previously only known in protein-based systems. Results Similarities of GlmY and GlmZ RNAs E. coli glmS is transcribed as part of a dicistronic glmUS operon mRNA [15]. Ribonuclease E cleaves the glmUS transcript within the glmU stop codon; this event generates a monocistronic glmS mRNA which strongly accumulates in E. coli pcnBΔ1 or ΔyhbJ, and causes GlmS overproduction [4,5]. We used primer extension assays to test whether constitutive GlmY or GlmZ expression also induces the accumulation of monocistronic glmS mRNA. To this end, E. coli strain MC4100 (wild type) was transformed with plasmids pPL-GlmY or pPL-GlmZ carrying the glmY or glmZ genes, respectively, under control of a constitutive PLlacO1 promoter. Figure 1 We previously established several glmS::gfp fusion plasmids as reporters of GlmY activity [3]. Of these, plasmid pJU-172 constitutively expresses a glmS::gfp fusion mRNA spanning the C-terminal glmU sequence (last 17 codons), the glmS 5′ UTR (161 nucleotides [nt]), and the first seven glmS codons translationally fused to gfp. This fusion is highly activated in the presence of the glmY expression plasmid, pPL-GlmY, suggesting that GlmY activates the glmS gene at the posttranscriptional level in a process that involves the glmS 5′ UTR. To test whether this fusion was also activated by GlmZ, the colony fluorescence of E. coli carrying pJU-172 in combination with a control plasmid (pJV300), or pPL-GlmY or pPL-GlmZ, was compared (Figure 1 The primary GlmY and GlmZ RNAs are of similar length (184 and 207 nt, respectively), and both sRNAs are subject to 3′ cleavage which yields an approximately 150-nt species [6,9]. Alignment of γ-proteobacterial glmZ sequences combined with RNA structure prediction (Figure S1) suggests that GlmZ adopts a secondary structure very similar to that of GlmY RNA, and identified a high degree of sequence identity between the E. coli GlmY and GlmZ RNAs (Figure 1 Hierarchy, and Not Redundancy, in the Action of GlmY and GlmZ sRNAs Given their apparent homology, we tested whether the two sRNAs could complement each other's function. Wild-type E. coli and isogenic ΔglmY or ΔglmZ mutant strains were transformed with pJV300, pPL-GlmY, or pPL-GlmZ, and cellular GlmS protein and glmS mRNA levels were determined upon growth to early stationary phase (Figure 2
Previous work had shown that the proteins Hfq and YhbJ are involved in glmS mRNA regulation [4]. We thus expressed GlmY and GlmZ in a larger array of E. coli mutants, including single or combined deletions of glmY, glmZ, hfq, and yhbJ (Figure S2). The results, in brief, showed that hfq is absolutely required for glmS activation by either sRNA, even in the absence of the negatively acting yhbJ. Expression of the two sRNAs in ΔyhbJ did not further elevate the already high glmS mRNA in this background. A ΔyhbJ ΔglmY ΔglmZ triple mutant displayed wild-type glmS mRNA levels; in this YhbJ-deficient mutant, GlmZ activated the glmS mRNA, whereas GlmY did not. Taken together, these experiments argued against the existence of a glmZ-independent pathway of GlmY action on glmS. Moreover, they argued that GlmZ acted independently of yhbJ, and likely directly upon glmS mRNA. Mechanism of glmS Activation by GlmZ RNA To understand the obvious hierarchy of the two sRNAs, we next addressed the molecular mechanism by which GlmZ activates the glmS mRNA. Work on rpoS mRNA activation by DsrA sRNA [16,17] had established an “anti-antisense” mechanism by which an sRNA competes with the formation of a stem-loop structure that normally sequesters the Shine-Dalgarno (SD) sequence of the target mRNA and inhibits its translation. Preliminary RNA structure probing experiments (unpublished data) and in silico prediction by others [4] prompted us to consider an anti-antisense mechanism of glmS mRNA activation. That is, the glmS SD is predicted to be occluded in a hairpin formed by the 5′ UTR of glmS mRNA (Figure 3
To test the validity of the above predictions, we mutated the 5' UTR of a glmS::gfp fusion. In the resulting mutant, glmS*::gfp, two point mutations (C−27 → G and G−36 → C; Figure 3 Full-Length GlmZ Is the Active RNA Species and Enhances glmS Translation To obtain direct evidence for translational glmS activation, in vitro synthesized glmS::gfp fusion mRNA was incubated with reconstituted 70S ribosomes in the presence or absence of GlmZ RNA, and GlmS::GFP fusion protein synthesis was monitored over the course of 30 min (Figure 4
The GlmY and Processed GlmZ RNAs Are Not Activators In Vitro We had previously established that in vivo, the primary GlmZ transcript is subject to 3′ end RNA processing, which generates a 153-nt species, here named GlmZ153 [9]. Kalamorz et al. [4] observed that GlmZ RNA processing is abrogated in a ΔyhbJ strain, and concomitantly, full-length GlmZ and glmS mRNA accumulate; this led the authors to hypothesize that only full-length GlmZ, and not GlmZ153, regulates glmS mRNA. Indeed, sequence inspection shows that GlmZ153 lacks the above proposed glmS target binding site (Figures 1 GlmY Promotes the Accumulation of Full-Length GlmZ RNA Given the above results, we speculated that GlmY activated glmS indirectly by means of increasing the amount of the full-length GlmZ RNA. If so, GlmZ levels should be elevated upon GlmY expression, which is indeed observed in bacteria carrying plasmid pPL-GlmY (compare lanes 1 and 2 in Figure 2
GlmY Is Essential for GlmZ Stabilization and GlmS Overproduction in a pcnB Mutant Given that GlmY antagonized the processing/degradation of GlmZ, it was likely that GlmZ accumulation resulted from increased GlmZ RNA stability. To prove GlmY-dependent RNA stability changes, we sought to identify a genetic background in which the GlmZ RNA and glmS mRNA levels change in response to presence or absence of the chromosomal glmY gene. Generally, two mutations were known to alter glmS mRNA levels, i.e., ΔyhbJ and pcnBΔ1 [4,5]. Deletion of glmY in these mutant backgrounds (shown for pncBΔ1 in Figure 6
Rifampicin-treatment experiments showed that the accumulation of processed GlmY and of full-length GlmZ in pcnBΔ1 cells was accompanied by increased stability of these RNA species (Figure 6 Loss of GlmY RNA Polyadenylation Causes GlmS Overproduction in E. coli pcnBΔ1 GlmS overproduction in E. coli pcnBΔ1 had been postulated to result from stabilization of no longer 3′ polyadenylated glmS mRNA [5]. However, the fact that a glmS::gfp fusion having a different 3′ end was equally activated in pcnBΔ1 (Figure 6 To determine whether GlmY, GlmZ or glmS transcripts were polyadenylated, we used an RNA circularization assay previously developed to assess the poly(A) status of chloroplast RNAs [19,20]. Briefly, total RNA of the MC4100 and pcnBΔ1 strains was treated with tobacco acid pyrophosphatase (to convert primary 5′ triphosphate to monophosphate groups), and subjected to 3′/5′ end circularization by T4 RNA ligase, and cDNA synthesis. Subsequently, 3′/5′ junction fragments were amplified by PCR (Figure 7
Discussion RNA-based regulatory mechanisms are commonly used to control the expression of metabolic genes. In addition to transcriptional and translational attenuators [21], trans-encoded sRNAs and cis-encoded metabolite-sensing aptamers have increasingly been recognized as mRNA regulators in metabolic pathways. Whereas cis-encoded metabolite sensors are prevalent in Gram-positive species, few such elements are known in Gram-negative bacteria [2,22–24]. Conversely, the number of E. coli sRNAs has come close to one hundred [25,26], and fewer sRNAs have been reported from Gram-positive species. Conforming to this obvious bias, the posttranscriptional control of glmS relies on a cis-encoded RNA sensor in B. subtilis, and on trans-encoded riboregulators in E. coli. Interestingly, this is reminiscent of the distinctly different RNA-based mechanisms controlling expression of the tryptophan biosynthetic operon in these two model bacteria [21]. In both cases, i.e., glmS and tryptophanase genes, the riboregulatory mechanisms facilitate feedback control of the encoded metabolic pathways [1,4,21]. The network of regulatory factors including the conserved GlmY and GlmZ sRNAs (ref. [3] and Figure S1) that controls the E. coli glmS mRNA appears to be well suited for this task, for it provides multiple entry points for the environmental signals that determine glmS epistasis. Figure 8
GlmZ is the only factor to directly activate glmS translation, and we have provided evidence that this process relies upon an anti-antisense mechanism that induces a translation-competent status of the mRNA. Similar to the DsrA-regulated rpoS mRNA [16,17], and other sRNA-activated mRNAs [30,31], the anti-antisense mechanism proposed here disrupts an inhibitory hairpin that sequesters the glmS RBS. Using purified components, we have been able to reconstitute glmS mRNA activation in vitro, proving that the ultimate step in this system requires only the translational machinery and GlmZ RNA. GlmZ exists in two forms, i.e., the primary 207-nt RNA which can activate glmS, and the processed, inactivated GlmZ153 species. Transcription of glmZ appears to be growth-rate controlled, and to be higher in fast-growing cells [9]. Although the upstream factor(s) that regulate glmZ transcription remain unknown, YhbJ acts downstream in the glmS activator cascade by regulating the availability of full-length GlmZ at the posttranscriptional level. YhbJ acts as a glmS repressor inasmuch as it promotes GlmZ processing [4], and we have demonstrated here that this event generates an inactive GlmZ species. Whether YhbJ, which is conserved in many bacteria [4], is an RNA-binding protein that interacts with GlmZ (or GlmY) is currently unknown, and our attempts to purify soluble YhbJ protein have so far been unsuccessful. GlmY is also upstream of GlmZ in the herein-described cascade, but in contrast to YhbJ, this RNA acts as a GlmZ/glmS activator. In our current working model (Figure 8 At the transcriptional level, the alternative sigma factor, σ54, may control glmY expression [3]. σ54 along with a yet to be identified activator protein could up-regulate glmY to bolster up GlmZ action upon nitrogen starvation. Similar to GlmZ, GlmY RNA is also repressed at the posttranscriptional level, albeit by polyadenylation. Loss of this repression in pncBΔ1 results in GlmY RNA stabilization and GlmS overproduction. However, under normal growth, the YhbJ-dependent GlmZ processing is likely the rate-limiting step since the GlmZ levels in ΔyhbJ are sufficiently high so that GlmY cannot further activate glmS expression (Figure S2). Nonetheless, little is known as to how RNA polyadenylation fluctuates in response to environmental conditions, and certain transcripts have been shown to become differentially polyadenylated in a growth rate–dependent manner [32]. Moreover, greater than 90% of all E. coli mRNAs expressed during exponential growth are controlled by polyadenlyation [33], but the number of mRNAs that are direct PAP I substrates is unknown. Notably, Joanny et al. [5] discussed the possibility that differential expression of regulatory sRNAs may account for some of these PAP I effects, similar to the stabilization of plasmid-borne cis-antisense RNAs that underlie alterations of plasmid copy number upon loss of polyadenylation [34,35]. It is worthwhile mentioning that similar to GlmY, additional chromosomal E. coli sRNAs are known to be polyadenylated [9]; at least one of these, SraL, is stabilized in a pcnB mutant of Salmonella [36]. Thus, it is reasonable to predict that additional mRNAs will be identified as differentially regulated in response to altered sRNA polyadenylation. The key finding of this paper is that two strikingly similar sRNAs, GlmY and GlmZ, form a regulatory cascade to regulate one and the same target mRNA. Following the original description of the E. coli CsrB and CsrC sRNAs, two homologous antagonists of CsrA protein [37,38], numerous families of homologous sRNAs have been reported (e.g., [8,39]). These include CsrB-like RNAs of other organisms [40], the E. coli OmrA/B sRNAs controlling outer membrane protein biogenesis [41], and a family of four to five Vibrio sRNAs regulating quorum sensing [42,43]. The common denominator in these systems is that the sRNAs act redundantly, or at least additively, and can to some degree substitute for each other's function. In contrast, the hierarchy of the sRNAs studied here is novel since GlmY strictly requires GlmZ for glmS activation. Our results have shown that GlmY can antagonize GlmZ 3′ end RNA processing, an event that one may refer to as controlled GlmZ inactivation. Given the related structures of the two sRNAs, this antagonism may involve some kind of molecular mimicry such that GlmY intercepts the factor (YhbJ?) that promotes GlmZ inactivation. If so, this mechanism would bear strong similarity to the activity of small anti-adaptor proteins, e.g., ComS and IraP, which interfere with the controlled proteolysis of transcriptional regulators, ComK or RpoS, respectively [44–46]. In analogy to the studies of ComS or IraP, the development of an in vitro system to study GlmZ degradation will help answer whether GlmY acts by molecular mimicry to save GlmZ from inactivation. In summary, the GlmYZ system represents a fine example of a regulatory circuit composed of RNA that is no less sophisticated than those composed of proteins. Given the many noncoding RNAs yet to be functionally characterized, we find it reasonable to speculate that hierarchically acting regulatory RNAs will also be discovered in other organisms. Materials and Methods Media and growth conditions. Growth in Luria–Bertani (LB) broth (220 rpm, 37 °C) or on LB agar plates at 37 °C was used throughout this study. A culture grown to an optical density at 600 nm (OD600) of 2 is referred to as an early stationary phase culture. Antibiotics (where appropriate) were used at the following concentrations: 100 mg/ml ampicillin, 50 mg/ml kanamycin, and 20 mg/ml chloramphenicol. For GlmY expression from pBAD-GlmY, cultures were induced with l-arabinose (0.2% final concentration). Rifampicin (Sigma) was added to the cultures at a final concentration of 500 μg/ml to block transcription. Bacterial strains. The E. coli strains used in this study are listed in Table 1. MC4100 was used as parental wild-type strain. To construct JVS-2058, the pcnBΔ1::kan allele of SK7988 [47] was moved into MC4100 by P1 transduction. JVS-8018 (ΔyhbJ::kan), JVS-8024 (ΔglmZ::kan), and JVS-8030 (ΔglmY::kan) were constructed by using the one-step gene inactivation protocol with PCR products obtained on pKD4 with primer pairs JVO-1951/-1952, JVO-1947/-1948, and JVO-1661/-1662, respectively (deoxyribonucleotides are listed in Table S1), followed by P1 transduction into MC4100. The kan marker of JVS-8018 was eliminated by using the FLP expression plasmid pCP20 [48], and the ΔglmY::kan (from JVS-8030), ΔglmZ::kan (from JVS-8024), and Δhfq::cat alleles were moved into this strain by P1 transduction to obtain JVS-8076 (Δyhb, ΔglmY::kan), JVS-8078 (Δyhb, ΔglmZ::kan), and JVS-8146 (ΔyhbJ, Δhfq::cat), respectively. Similarly, the kan markers of JVS-8076 and JVS-8030 were eliminated using pCP20, and the ΔglmZ::kan (from JVS-8024) allele moved into the respective strains to construct JVS-8111 (ΔyhbJ ΔglmY ΔglmZ::kan) and JVS-8113 (ΔglmY ΔglmZ::kan).
JVS-8213 (pcnBΔ1::kan ΔglmY::cat) and JVS-8241(pcnBΔ1::kan ΔglmZ::cat) were derived from strain JVS-2058 (pcnBΔ1::kan) by using the one-step gene inactivation protocol with PCR products obtained on pKD3 [48] with primer pairs JVO-1661/-1662 and JVO-1947/-1948, respectively. Elimination of the cat markers of JVS-8213 and JVS-8241 resulted in strains JVS-8217 (pcnBΔ1::kan ΔglmY) and JVS-8242 (pcnBΔ1::kan ΔglmZ), respectively. Plasmids. Plasmids used in this study are listed in Table 2. To construct plasmid pPL-GlmZ, an E. coli glmZ fragment was amplified with oligos jb-103-H and jb-103-I, and inserted by blunt end and EcoRI cloning into vector pZE12-luc [49], following a previously published protocol [50]. Plasmid pPL-GlmZ* was constructed by introduction of two point mutations into pPL-GlmZ by PCR amplification of this plasmid using primers JVO-2609/-2610, followed by self-ligation of the PCR product.
Construction of plasmid pBAD-GlmY (l-arabinose-inducible glmY expression) followed the previously published protocol by [51]. Briefly, vector pBAD-His-myc was amplified by PCR using sense primer JVO-0901 (adds an XbaI restriction site upstream of the rrnB terminator) and antisense primer JVO-0900 (anneals to the −1 position of the PBAD promoter). A glmY-derived PCR product amplified with primers JVO-1399/-0670 was digested with XbaI, and inserted into the above-described plasmid backbone (treated with XbaI) to yield pBAD-GlmY. For the construction of a low-copy complementation plasmid of glmY expression, the glmY gene including an approximately 360-nt upstream region was PCR amplified with primers JVO-0670/-2019, the resulting product digested with AatII and XbaI, and ligated to the AatII/XbaI digested plasmid pXG-1 [52] to yield pglmY. The glmS::gfp fusion plasmid, pJU-172, which expresses a FlacZ::glmU-glmS::gfp mini-operon, was constructed by inserting a BfrBI/NheI-digested PCR product obtained with primers JVO-1270/-1294 into the operon GFP fusion vector pXG-30 [52] digested with the same restriction enzymes. In the resulting plasmid, the C-terminal sequence (17 amino acids [aa]) of glmU is fused to the carboxy terminus of a FLAG epitope-tagged, truncated lacZ gene (FlacZ′). The glmS gene (first 7 aa) is fused to the N-terminus of gfp. The corresponding glmS*::gfp fusion plasmid, pJU-355, carrying compensatory base-pair changes was constructed by self-ligation of a PCR product obtained on plasmid pJU-172 and using primers JVO-2605/-2606. Whole-cell protein fractions and Western blot. Protein sample preparation and western blotting was carried out as described [52]. An amount of whole-cell protein fractions corresponding to 0.01 OD culture volume was separated by 12% SDS-PAGE and transferred onto a PVDF membrane (PerkinElmer). A polyclonal serum was used 1:5,000 in 3% BSA, TBST20 to detect GlmS. GFP and GroEL detection was carried out as described previously [52]. Whenever GlmS and GroEL were detected on the same membrane, blots were first hybridized with α-GlmS, stripped using Roti-Free solution (Roth) according to the manufacturer's protocol, and afterwards hybridized with α-GroEL. Blots were developed using Western Lightning reagent (PerkinElmer), and signals detected with a Fuji LAS-3000 charge-coupled device (CCD) camera. RNA isolation and Northern blot detection. RNA using TRIZOL reagent (Invitrogen) or the Promega SV total RNA isolation kit were performed as described [51,52]. Separation of 5 μg of total RNA (samples prepared with TRIZOL) was on 5% polyacrylamide gels containing 8.3 M urea, or of 12 μg of total RNA (samples prepared with Promega SV totalRNA) on 1.5% agarose gels containing 2.2 M formaldehyde, and northern detection was carried out as described [52]. RNA stability experiments were performed as described in [6]. GlmY, GlmZ, and 5S rRNA were detected using 5′ end-labeled oligodeoxyribonucleotide JVO-1730, −1697, and −0322, respectively. glmS mRNA was detected using an RNA probe derived from in vitro transcription of a PCR fragment (primers: JVO-1598/-1599; T7 promoter is added by JVO-1599) in the presence of [α-32P] UTP with Ambion's T7 polymerase Maxiscript kit. Signals were visualized on a phosphorimager (Phosphorimager, FLA-3000 Series; Fuji), and band intensities quantified with AIDA software (Raytest). In vivo whole-cell colony plate fluorescence imaging. E. coli strains expressing plasmid-borne gfp fusions were streaked on standard LB plates supplemented with the appropriate antibiotics. After overnight growth, colonies were photographed in a FUJI LAS-3000 image analyzer using a CCD camera with a 510-nm emission filter and excitation at 460 nm. cDNA synthesis and cloning for 3′ end sequencing. The procedure for RNA 3′ end sequencing has been described previously [20] and was used with some modifications. A total of 8 μg of DNA-free total RNA prepared from early stationary phase cultures was treated with ten units tobacco acid pyrophosphatase (Epicentre) for 30 min at 37 °C to convert 5′ triphosphate groups of primary transcripts to 5′ monophosphates. Following organic extraction, RNA was treated overnight at 17 °C with 40 units of T4 RNA ligase (New England Biolabs) to circularize transcripts. Following organic extraction and ethanol precipitation, 1.5 μg of self-ligated RNA was converted to cDNA using 100 pmol random hexamer primers and the Superscript III (200 units) reverse transcription kit (Invitrogen) in a 20-μl reaction. Herein, 10-min incubation at 25 °C was carried out before addition of the reverse transcriptase, followed by four subsequent 15-min incubation steps at 42 °C, 50 °C, 55 °C, and 60 °C. After heat inactivation of the reverse transcriptase for 5 min at 85 °C, samples were treated with one unit of RNase H (New England Biolabs) at 37 °C for 20 min. A total of 1 μl of the reaction served as template in a subsequent standard 25-μl PCR reaction using 0.5 units Taq polymerase (New England Biolabs) and primer pairs designed to amplify products representing successful self-ligated GlmY (primer JVO-2349/-2355), GlmZ (primer JVO-2350/-2356), and glmS (primer JVO-2022/-2388) transcripts. PCR products were separated by 3% agarose gel electrophoresis, and fragments of the expected size were excised, purified, and cloned into the pCR 2.1-TOPO vector (Invitrogen). Colony PCR products obtained on positive clones with standard primers M13 Forward and M13 Reverse were sequenced with primer M13 Reverse. Primer extension. The processing site within the dicistronic glmUS mRNA was determined by primer extension according to the SuperscriptIII protocol (Invitrogen). In brief, 10 μg of total RNA prepared with the Promega SV total RNA isolation kit from cultures grown to an OD600 of 2 were incubated with 2 pmol of 5′ end-labeled primer JVO-2022 (anneals to positions −19 to −2 relative to the glmS start codon) for 5 min at 65 °C, followed by 5 min on ice. The samples were adjusted to a final volume of 20 μl, containing 1× first strand buffer, 0.5 mM each of dATP, dGTP, dCTP, and dTTP, 5 mM DTT, 20 units superasin RNase inhibitor (Ambion), and 200 units SuperscriptIII (Invitrogen). Reverse transcription was carried out for 60 min at 50 °C, followed by inactivation of the enzyme at 70 °C for 15 min. After treatment with 2 units RNaseH (New England Biolabs), 3 μl of the reactions was separated on a denaturing 6% polyacrylamide gel containing 7 M urea. The sequencing ladder was established by using the CycleReader DNA sequencing kit (Fermentas) according to the manufacturer's protocol with 5′ end-labeled primer JVO-2022 on a PCR product obtained on E. coli K12 DNA with primer pair JVO-1177/-2022. In vitro translation assay. Translation reactions were carried out using PURESYSTEM (PGM-PURE2048C; Cosmo Bio Co.) according to the manufacturer's instructions. The 10-μl reactions contained, in addition to 70S ribosomes, 1 pmol glmS::gfp mRNA template and Hfq, as well as GlmY and GlmZ sRNA variants (see Figure 4 RNAs were synthesized in vitro using the AmpliScribe T7-flash kit (Epicentre) according to the manufacturer's instructions. Templates for glmS::gfp, GlmY, GlmZ, and GlmZ153 T7 in vitro transcription were established by PCR on plasmids pJU-172 (for T7-glmS::gfp), pPL-GlmY (for T7-GlmY), and pPL-GlmZ (for T7-GlmZ and T7-GlmZ153) using primer pairs JVO-1866/-pZE-T1, JVO-1560/-1562, JVO-2130/-2427, and JVO-2130/-2528, respectively. Figure S1: Conservation of Enterobacterial glmZ Genes (A) Alignment of glmZ genes identified in different enterobacteria. The transcriptional start site (+1) and a putative transcriptional terminator (arrowheads) are denoted for the E. coli glmZ. A putative −10 element of σ70-type promoters is underlined. Sequences were collected from the following genomes (accession numbers in parentheses): E. coli K12 (NC_000913), Shigella flexneri 2a strain 301 (NC_004337), Salmonella typhimurium LT2 (NC_003197), Yersinia pestis CO92 (NC_003143), Erwinia carotovora subsp. atroseptica (NC_004547), and Photorhabdus luminescens subsp. laumondii (NC_005126), and the unfinished genome sequences of Klebsiella pneumoniae strain Kp342 (http://www.tigr.org) and of Serratia marcescens strain Db11 (http://www.sanger.ac.uk). The alignment was computed with Multalign (http://bioinfo.genopole-toulouse.prd.fr/multalin/multalin.html; [53]). (B) Secondary structure of E. coli GlmZ RNA predicted by Mfold [54]. Residues that are conserved in the GlmZ RNAs shown in (A) are shadowed. Vertical arrows indicate previously mapped 3′ processing sites [9]. The residues predicted by the RNA-Hybrid program [55] to interact with the glmS-leader are highlighted in red. (54 KB PDF) Click here for additional data file.(54K, pdf) Figure S2: Effect of GlmY and GlmZ Expression in Different E. coli Mutant Strains Western and northern blot analyses comparing the effects of GlmY and GlmZ expression in MC4100, Δhfq::cat, JVS-8018 (ΔyhbJ), JVS-8146 (ΔyhbJ Δhfq), JVS-8113 (ΔglmY ΔglmZ), or JVS-8111 (ΔyhbJ ΔglmY ΔglmZ). Each of these strains carried plasmids pJV300 (“contr” lanes), pPL-GlmY (“GlmY” lanes), or pPL-GlmZ (“GlmZ” lanes). Whole-cell protein and total RNA samples were prepared from early stationary phase cultures. Western blots were probed with sera specific for GlmS (top panel) or GroEL (loading control; second panel from top) proteins. For northern blot detection of glmS mRNA (third panel from top), 12 μg of total RNA per lane was separated on a 1.5% agarose-formaldehyde gel. To detect GlmY and GlmZ, 5 μg of total RNA was separated on a denaturing 5% PAA gel (fourth and fifth panels from top). The 5S rRNA (bottom panel) probing confirmed equal amounts of RNA in each sample. Black lollipops indicate the primary GlmY or GlmZ transcripts; open lollipops the processed, approximately 150-nt RNA species. (210 KB PDF) Click here for additional data file.(211K, pdf) Figure S3: Induction of GlmY Expression from an IPTG-Inducible Promoter E. coli Top10F′ (lacIq; Invitrogen) was transformed with control vector, pJV300, or the IPTG-inducible glmY expression plasmid, pPL-GlmY (as indicated above the panels). Transformants were grown to early stationary phase, and treated with 0.5 mM IPTG to induce glmY expression. RNA was prepared prior to or at the indicated time-intervals (in minutes) upon induction, and subjected to northern analysis to detect changes in GlmY, GlmZ, and glmS mRNA expression. Black lollipops indicate the primary GlmY or GlmZ transcripts, open lollipops the processed, approximately 150-nt species of these sRNAs. (60 KB PDF) Click here for additional data file.(61K, pdf) Figure S4: Effect of glmY and glmZ Deletion or Overexpression in E. coli yhbJ (A) Activation of a translational glmS::gfp fusion in a ΔyhbJ background requires glmZ, but not glmY. Colony fluorescence of E. coli MC4100 (wt) and mutant strains JVS-8018 (ΔyhbJ), JVS-8076 (ΔyhbJ ΔglmY), JVS-8078 (ΔyhbJ ΔglmZ) harboring plasmid glmS::gfp, or pXG-1 (gfp control plasmid). Images were obtained in the fluorescence (left panel) and visual light (right panel) mode. (B) Western and northern blot analyses (as in Figure S2) comparing the effects of GlmY and GlmZ expression in MC4100, JVS-8030 (ΔglmY), JVS-8024 (ΔglmZ), JVS-8018 (ΔyhbJ), JVS-8076 (ΔyhbJ ΔglmY), and JVS-8078 (ΔyhbJ ΔglmZ). (169 KB PDF) Click here for additional data file.(169K, pdf) Table S1: List of Deoxyribonucleotides Sequences are given in 5′ → 3′ direction; “P~” denotes a 5′ monophosphate. (76 KB DOC) Click here for additional data file.(76K, doc) Acknowledgments We thank M. Badet-Denisot for GlmS antiserum; S. Kushner for strains; S. Gottesman, C. M. Sharma, K. Papenfort, U. Bläsi, and C. Yanofsky for insightful comments on the manuscript. We are indebted to H. Aiba who kindly told us of the PURESYSTEM. Abbreviations
Footnotes Author contributions. JHU and JV conceived and designed the experiments. JU performed the experiments. JHU and JV analyzed the data. JV wrote the paper. Funding. JHU was supported by grants from Deutsche Forschungsgemeinschaft, Germany (DFG; VO 875/1–1,3). Competing interests. The authors have declared that no competing interests exist. References
|
PubMed related articles
Your browsing activity is empty. Activity recording is turned off. |
||||||||||||||||||||||||||||||||||||||
Nature. 2004 Mar 18; 428(6980):281-6.
[Nature. 2004]Proc Natl Acad Sci U S A. 2004 Apr 27; 101(17):6421-6.
[Proc Natl Acad Sci U S A. 2004]J Mol Biol. 2007 Oct 26; 373(3):521-8.
[J Mol Biol. 2007]Nucleic Acids Res. 2007; 35(8):2494-502.
[Nucleic Acids Res. 2007]Nucleic Acids Res. 2003 Nov 15; 31(22):6435-43.
[Nucleic Acids Res. 2003]Curr Biol. 2001 Sep 4; 11(17):1369-73.
[Curr Biol. 2001]Genes Dev. 2001 Jul 1; 15(13):1637-51.
[Genes Dev. 2001]Curr Biol. 2001 Jun 26; 11(12):941-50.
[Curr Biol. 2001]J Mol Biol. 2007 Oct 26; 373(3):521-8.
[J Mol Biol. 2007]J Mol Biol. 2007 Oct 26; 373(3):521-8.
[J Mol Biol. 2007]Nucleic Acids Res. 2003 Nov 15; 31(22):6435-43.
[Nucleic Acids Res. 2003]Curr Biol. 2001 Jun 26; 11(12):941-50.
[Curr Biol. 2001]Mol Microbiol. 2007 Sep; 65(6):1518-33.
[Mol Microbiol. 2007]Nucleic Acids Res. 2007; 35(8):2494-502.
[Nucleic Acids Res. 2007]Proc Natl Acad Sci U S A. 1992 Nov 1; 89(21):10380-4.
[Proc Natl Acad Sci U S A. 1992]IUBMB Life. 2004 Oct; 56(10):585-94.
[IUBMB Life. 2004]Cell. 2002 Nov 27; 111(5):611-3.
[Cell. 2002]EMBO J. 1995 Aug 15; 14(16):3958-65.
[EMBO J. 1995]Mol Microbiol. 2007 Sep; 65(6):1518-33.
[Mol Microbiol. 2007]Nucleic Acids Res. 2007; 35(8):2494-502.
[Nucleic Acids Res. 2007]J Mol Biol. 2007 Oct 26; 373(3):521-8.
[J Mol Biol. 2007]Nucleic Acids Res. 2003 Nov 15; 31(22):6435-43.
[Nucleic Acids Res. 2003]Curr Biol. 2001 Jun 26; 11(12):941-50.
[Curr Biol. 2001]Mol Microbiol. 2007 Sep; 65(6):1518-33.
[Mol Microbiol. 2007]Proc Natl Acad Sci U S A. 1998 Oct 13; 95(21):12462-7.
[Proc Natl Acad Sci U S A. 1998]Proc Natl Acad Sci U S A. 1998 Oct 13; 95(21):12456-61.
[Proc Natl Acad Sci U S A. 1998]Mol Microbiol. 2007 Sep; 65(6):1518-33.
[Mol Microbiol. 2007]J Mol Biol. 2007 Oct 26; 373(3):521-8.
[J Mol Biol. 2007]Mol Microbiol. 2007 Sep; 65(6):1518-33.
[Mol Microbiol. 2007]Curr Biol. 2001 Jun 26; 11(12):941-50.
[Curr Biol. 2001]Mol Microbiol. 2007 Sep; 65(6):1518-33.
[Mol Microbiol. 2007]J Bacteriol. 1995 Jul; 177(14):4121-30.
[J Bacteriol. 1995]Mol Microbiol. 2007 Sep; 65(6):1518-33.
[Mol Microbiol. 2007]Nucleic Acids Res. 2007; 35(8):2494-502.
[Nucleic Acids Res. 2007]Nucleic Acids Res. 2007; 35(8):2494-502.
[Nucleic Acids Res. 2007]EMBO J. 2002 Jul 15; 21(14):3794-803.
[EMBO J. 2002]RNA. 2001 Feb; 7(2):285-92.
[RNA. 2001]RNA. 2007 Aug; 13(8):1141-54.
[RNA. 2007]Proc Natl Acad Sci U S A. 2004 Apr 27; 101(17):6421-6.
[Proc Natl Acad Sci U S A. 2004]Trends Biochem Sci. 2004 Jan; 29(1):11-7.
[Trends Biochem Sci. 2004]Cell. 2003 May 30; 113(5):577-86.
[Cell. 2003]Crit Rev Biochem Mol Biol. 2005 Mar-Apr; 40(2):93-113.
[Crit Rev Biochem Mol Biol. 2005]J Mol Biol. 2007 Oct 26; 373(3):521-8.
[J Mol Biol. 2007]Nucleic Acids Res. 2007; 35(8):2494-502.
[Nucleic Acids Res. 2007]EMBO J. 1995 Aug 15; 14(16):3958-65.
[EMBO J. 1995]Mol Microbiol. 2007 Sep; 65(6):1518-33.
[Mol Microbiol. 2007]Genes Dev. 2005 Nov 1; 19(21):2526-33.
[Genes Dev. 2005]J Mol Biol. 2007 Oct 26; 373(3):521-8.
[J Mol Biol. 2007]Nucleic Acids Res. 2007; 35(8):2494-502.
[Nucleic Acids Res. 2007]Proc Natl Acad Sci U S A. 1998 Oct 13; 95(21):12462-7.
[Proc Natl Acad Sci U S A. 1998]Proc Natl Acad Sci U S A. 1998 Oct 13; 95(21):12456-61.
[Proc Natl Acad Sci U S A. 1998]Mol Microbiol. 2007 Jun; 64(5):1260-73.
[Mol Microbiol. 2007]Proc Natl Acad Sci U S A. 2007 Jul 3; 104(27):11145-9.
[Proc Natl Acad Sci U S A. 2007]Curr Biol. 2001 Jun 26; 11(12):941-50.
[Curr Biol. 2001]Mol Microbiol. 2007 Sep; 65(6):1518-33.
[Mol Microbiol. 2007]J Mol Biol. 2007 Oct 26; 373(3):521-8.
[J Mol Biol. 2007]EMBO Rep. 2003 Feb; 4(2):172-7.
[EMBO Rep. 2003]Nucleic Acids Res. 2006; 34(19):5695-704.
[Nucleic Acids Res. 2006]Nucleic Acids Res. 2007; 35(8):2494-502.
[Nucleic Acids Res. 2007]Proc Natl Acad Sci U S A. 1993 Jul 15; 90(14):6756-60.
[Proc Natl Acad Sci U S A. 1993]Mol Microbiol. 1997 Nov; 26(3):493-504.
[Mol Microbiol. 1997]Mol Microbiol. 2003 May; 48(3):657-70.
[Mol Microbiol. 2003]J Biol Chem. 1997 Jul 11; 272(28):17502-10.
[J Biol Chem. 1997]Genes Dev. 2001 Jul 1; 15(13):1637-51.
[Genes Dev. 2001]Genome Biol. 2005; 6(9):R73.
[Genome Biol. 2005]Proc Natl Acad Sci U S A. 2005 Nov 22; 102(47):17136-41.
[Proc Natl Acad Sci U S A. 2005]Genes Dev. 2006 Apr 1; 20(7):884-97.
[Genes Dev. 2006]Mol Microbiol. 1999 May; 32(4):799-812.
[Mol Microbiol. 1999]Proc Natl Acad Sci U S A. 1995 Mar 14; 92(6):1807-11.
[Proc Natl Acad Sci U S A. 1995]Proc Natl Acad Sci U S A. 2000 Jun 6; 97(12):6640-5.
[Proc Natl Acad Sci U S A. 2000]Proc Natl Acad Sci U S A. 2000 Jun 6; 97(12):6640-5.
[Proc Natl Acad Sci U S A. 2000]Nucleic Acids Res. 1997 Mar 15; 25(6):1203-10.
[Nucleic Acids Res. 1997]Curr Biol. 2004 Dec 29; 14(24):2271-6.
[Curr Biol. 2004]Mol Microbiol. 2006 Dec; 62(6):1674-88.
[Mol Microbiol. 2006]Nucleic Acids Res. 2007; 35(3):1018-37.
[Nucleic Acids Res. 2007]Nucleic Acids Res. 2007; 35(3):1018-37.
[Nucleic Acids Res. 2007]Nucleic Acids Res. 2007; 35(3):1018-37.
[Nucleic Acids Res. 2007]Mol Microbiol. 2006 Dec; 62(6):1674-88.
[Mol Microbiol. 2006]Nucleic Acids Res. 2007; 35(3):1018-37.
[Nucleic Acids Res. 2007]Nucleic Acids Res. 2003 Nov 15; 31(22):6435-43.
[Nucleic Acids Res. 2003]RNA. 2001 Feb; 7(2):285-92.
[RNA. 2001]Nucleic Acids Res. 2007; 35(3):1018-37.
[Nucleic Acids Res. 2007]Nucleic Acids Res. 1988 Nov 25; 16(22):10881-90.
[Nucleic Acids Res. 1988]Nucleic Acids Res. 2003 Jul 1; 31(13):3406-15.
[Nucleic Acids Res. 2003]Curr Biol. 2001 Jun 26; 11(12):941-50.
[Curr Biol. 2001]RNA. 2004 Oct; 10(10):1507-17.
[RNA. 2004]